Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
NBIX's Cash to Debt is ranked higher than
90% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. NBIX: No Debt )
NBIX' s 10-Year Cash to Debt Range
Min: 1.72   Max: No Debt
Current: No Debt

Interest Coverage No Debt
NBIX's Interest Coverage is ranked higher than
95% of the 488 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.25 vs. NBIX: No Debt )
NBIX' s 10-Year Interest Coverage Range
Min: 2.5   Max: 9999.99
Current: No Debt

2.5
9999.99
F-Score: 3
Z-Score: 18.07
M-Score: 1579.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -2312.56
NBIX's Operating margin (%) is ranked lower than
55% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.92 vs. NBIX: -2312.56 )
NBIX' s 10-Year Operating margin (%) Range
Min: -17340.03   Max: 43.82
Current: -2312.56

-17340.03
43.82
Net-margin (%) -2146.92
NBIX's Net-margin (%) is ranked lower than
55% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.26 vs. NBIX: -2146.92 )
NBIX' s 10-Year Net-margin (%) Range
Min: -16936.19   Max: 48.53
Current: -2146.92

-16936.19
48.53
ROE (%) -27.02
NBIX's ROE (%) is ranked higher than
52% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.33 vs. NBIX: -27.02 )
NBIX' s 10-Year ROE (%) Range
Min: -250.63   Max: 94.61
Current: -27.02

-250.63
94.61
ROA (%) -22.50
NBIX's ROA (%) is ranked higher than
51% of the 814 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.07 vs. NBIX: -22.50 )
NBIX' s 10-Year ROA (%) Range
Min: -62.22   Max: 26.57
Current: -22.5

-62.22
26.57
ROC (Joel Greenblatt) (%) -2686.09
NBIX's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.20 vs. NBIX: -2686.09 )
NBIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2323.57   Max: 2175.88
Current: -2686.09

-2323.57
2175.88
Revenue Growth (%) -60.10
NBIX's Revenue Growth (%) is ranked lower than
55% of the 655 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. NBIX: -60.10 )
NBIX' s 10-Year Revenue Growth (%) Range
Min: -76.6   Max: 175.9
Current: -60.1

-76.6
175.9
EBITDA Growth (%) 47.00
NBIX's EBITDA Growth (%) is ranked higher than
94% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. NBIX: 47.00 )
NBIX' s 10-Year EBITDA Growth (%) Range
Min: -64.4   Max: 111.1
Current: 47

-64.4
111.1
EPS Growth (%) 66.30
NBIX's EPS Growth (%) is ranked higher than
96% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. NBIX: 66.30 )
NBIX' s 10-Year EPS Growth (%) Range
Min: -69.8   Max: 66.3
Current: 66.3

-69.8
66.3
» NBIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

NBIX Guru Trades in Q3 2013

Paul Tudor Jones 30,900 sh (New)
Pioneer Investments 474,486 sh (+91.33%)
George Soros Sold Out
Steven Cohen 3,900 sh (-99.44%)
» More
Q4 2013

NBIX Guru Trades in Q4 2013

Pioneer Investments 524,523 sh (+10.55%)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
Q1 2014

NBIX Guru Trades in Q1 2014

Pioneer Investments 434,514 sh (-17.16%)
» More
Q2 2014

NBIX Guru Trades in Q2 2014

Pioneer Investments 511,617 sh (+17.74%)
» More
» Details

Insider Trades

Latest Guru Trades with NBIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2013-09-30 Sold Out 0.03%$10.6 - $16.7 $ 16.117%0
George Soros 2013-06-30 New Buy0.03%$10.9 - $13.57 $ 16.131%200000
Joel Greenblatt 2012-12-31 Sold Out 0.13%$6.88 - $8.66 $ 16.1112%0
Joel Greenblatt 2012-06-30 Add 23.8%0.03%$6.31 - $8.06 $ 16.1124%259903
George Soros 2012-06-30 Sold Out 0.02%$6.31 - $8.06 $ 16.1124%0
Joel Greenblatt 2012-03-31 New Buy0.15%$7.33 - $9.79 $ 16.1102%209930
George Soros 2012-03-31 New Buy0.02%$7.33 - $9.79 $ 16.1102%150000
George Soros 2011-12-31 Sold Out 0.0018%$5.5 - $8.58 $ 16.1138%0
George Soros 2011-09-30 Reduce -23.93%$5.59 - $8.44 $ 16.1140%17800
George Soros 2011-06-30 Add 90.24%$6.82 - $8.3 $ 16.1114%23400
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.16
NBIX's P/B is ranked higher than
61% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.39 vs. NBIX: 5.16 )
NBIX' s 10-Year P/B Range
Min: 0.9   Max: 108
Current: 5.16

0.9
108
EV-to-EBIT -20.32
NBIX's EV-to-EBIT is ranked higher than
57% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.17 vs. NBIX: -20.32 )
NBIX' s 10-Year EV-to-EBIT Range
Min: 6   Max: 426.3
Current: -20.32

6
426.3
Current Ratio 16.39
NBIX's Current Ratio is ranked higher than
98% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.28 vs. NBIX: 16.39 )
NBIX' s 10-Year Current Ratio Range
Min: 1.63   Max: 24.56
Current: 16.39

1.63
24.56
Quick Ratio 16.39
NBIX's Quick Ratio is ranked higher than
98% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. NBIX: 16.39 )
NBIX' s 10-Year Quick Ratio Range
Min: 1.63   Max: 24.56
Current: 16.39

1.63
24.56

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.56
NBIX's Price/Net Cash is ranked higher than
94% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. NBIX: 7.56 )
NBIX' s 10-Year Price/Net Cash Range
Min: 2.62   Max: 254.67
Current: 7.56

2.62
254.67
Price/Net Current Asset Value 7.46
NBIX's Price/Net Current Asset Value is ranked higher than
90% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. NBIX: 7.46 )
NBIX' s 10-Year Price/Net Current Asset Value Range
Min: 2.56   Max: 103.76
Current: 7.46

2.56
103.76
Price/Tangible Book 5.16
NBIX's Price/Tangible Book is ranked higher than
69% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. NBIX: 5.16 )
NBIX' s 10-Year Price/Tangible Book Range
Min: 1.11   Max: 101.67
Current: 5.16

1.11
101.67
Earnings Yield (Greenblatt) 0.20
NBIX's Earnings Yield (Greenblatt) is ranked lower than
55% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. NBIX: 0.20 )
NBIX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 16.8
Current: 0.2

0.2
16.8
Forward Rate of Return (Yacktman) -2.05
NBIX's Forward Rate of Return (Yacktman) is ranked higher than
63% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.05 vs. NBIX: -2.05 )
NBIX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -26.7   Max: -7.3
Current: -2.05

-26.7
-7.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:NB3.Germany
Neurocrine Biosciences, Inc., a California corporation was incorporated in January 1992 and was reincorporated in Delaware in May 1996. The Company discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders. Its product candidates address some of the largest pharmaceutical markets in the world, including insomnia, anxiety, depression, various female and male health disorders, multiple sclerosis, diabetes and other neurological and endocrine related diseases and disorders. The Company currently has eleven programs in various stages of research and development, including six programs in clinical development. While it independently develops many of its product candidates, it has entered into collaboration for several of its programs. Its clinical development program, elagolix, is a drug candidate for the treatment of endometriosis and uterine fibroids. The Company faces competition from biotechnology and pharmaceutical companies, research institutions, government agencies and academic institutions.
» More Articles for NBIX

Headlines

Articles On GuruFocus.com
Weekly Insider Sells Highlight: ORCL, TWC, FB, NBIX Jan 13 2014 
5 Strong Healthcare Stocks For 2012 Mar 24 2012 
Consider These 5 Healthcare Stocks Now Mar 21 2012 
Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,320 Shares Mar 02 2011 
Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,400 Shares Mar 02 2011 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Oct 29 2010 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Jul 29 2010 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Apr 29 2010 
Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,650 Shares Mar 03 2010 
Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,609 Shares Mar 03 2010 

More From Other Websites
Range-bound play in Neurocrine Sep 24 2014
Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference Sep 03 2014
NEUROCRINE BIOSCIENCES INC Financials Aug 15 2014
NBIX: Neurocrine To Move Tardive Dyskinesia Drug Into Phase 3 Aug 08 2014
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 06 2014
Neurocrine Biosciences Reports Second Quarter 2014 Results Aug 06 2014
Q2 2014 Neurocrine Biosciences Earnings Release - After Market Close Aug 06 2014
Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial... Jul 29 2014
2 Biotechs Race To Treat Movement Disorders Jun 27 2014
Neurocrine In "Hurry Up And Wait" Mode Jun 11 2014
Neurocrine Biosciences Presenting NBI-98854 Scientific Abstracts And Posters At The International... Jun 11 2014
Neurocrine Biosciences To Present At The Jefferies 2014 Global Healthcare Conference May 29 2014
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 22 2014
Neurocrine Biosciences' (NBIX) CEO Kevin Gorman Presents at Bank of America Merrill Lynch 2014... May 15 2014
Neurocrine Biosciences' (NBIX) CEO Kevin Gorman on Deutsche Bank 39th Annual Health Care Conference... May 10 2014
Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference May 08 2014
NEUROCRINE BIOSCIENCES INC Files SEC form 10-Q, Quarterly Report May 01 2014
Neurocrine Biosciences to Present at Deutsche Bank's 39th Annual Health Care Conference May 01 2014
Neurocrine Biosciences' CEO Discusses Q1 2014 Results - Earnings Call Transcript Apr 30 2014
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Apr 30 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK